Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Wang, Y, Li, L, Douville, C, Cohen, JD, Yen, T-T, Kinde, I, Sundfelt, K, Kjær, SK, Hruban, RH, Shih, I-M, Wang, T-L, Kurman, RJ, Springer, S, Ptak, J, Popoli, M, Schaefer, J, Silliman, N, Dobbyn, L, Tanner, EJ, Angarita, A, Lycke, M, Jochumsen, K, Afsari, B, Danilova, L, Levine, DA, Jardon, K, Zeng, X, Arseneau, J, Fu, L, Diaz, LA, Karchin, R, Tomasetti, C, Kinzler, KW, Vogelstein, B, Fader, AN, Gilbert, L & Papadopoulos, N 2018, 'Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers' Science translational medicine, bind 10, nr. 433, s. eaap8793. https://doi.org/10.1126/scitranslmed.aap8793

APA

CBE

Wang Y, Li L, Douville C, Cohen JD, Yen T-T, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih I-M, Wang T-L, Kurman RJ, Springer S, Ptak J, Popoli M, Schaefer J, Silliman N, Dobbyn L, Tanner EJ, Angarita A, Lycke M, Jochumsen K, Afsari B, Danilova L, Levine DA, Jardon K, Zeng X, Arseneau J, Fu L, Diaz LA, Karchin R, Tomasetti C, Kinzler KW, Vogelstein B, Fader AN, Gilbert L, Papadopoulos N. 2018. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science translational medicine. 10(433):eaap8793. https://doi.org/10.1126/scitranslmed.aap8793

MLA

Vancouver

Author

Wang, Yuxuan ; Li, Lu ; Douville, Christopher ; Cohen, Joshua D ; Yen, Ting-Tai ; Kinde, Isaac ; Sundfelt, Karin ; Kjær, Susanne K ; Hruban, Ralph H ; Shih, Ie-Ming ; Wang, Tian-Li ; Kurman, Robert J ; Springer, Simeon ; Ptak, Janine ; Popoli, Maria ; Schaefer, Joy ; Silliman, Natalie ; Dobbyn, Lisa ; Tanner, Edward J ; Angarita, Ana ; Lycke, Maria ; Jochumsen, Kirsten ; Afsari, Bahman ; Danilova, Ludmila ; Levine, Douglas A ; Jardon, Kris ; Zeng, Xing ; Arseneau, Jocelyne ; Fu, Lili ; Diaz, Luis A ; Karchin, Rachel ; Tomasetti, Cristian ; Kinzler, Kenneth W ; Vogelstein, Bert ; Fader, Amanda N ; Gilbert, Lucy ; Papadopoulos, Nickolas. / Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. I: Science translational medicine. 2018 ; Bind 10, Nr. 433. s. eaap8793.

Bibtex

@article{9b75098a05074ae3a021209da31b429d,
title = "Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers",
abstract = "We report the detection of endometrial and ovarian cancers based on genetic analyses of DNA recovered from the fluids obtained during a routine Papanicolaou (Pap) test. The new test, called PapSEEK, incorporates assays for mutations in 18 genes as well as an assay for aneuploidy. In Pap brush samples from 382 endometrial cancer patients, 81{\%} [95{\%} confidence interval (CI), 77 to 85{\%}] were positive, including 78{\%} of patients with early-stage disease. The sensitivity in 245 ovarian cancer patients was 33{\%} (95{\%} CI, 27 to 39{\%}), including 34{\%} of patients with early-stage disease. In contrast, only 1.4{\%} of 714 women without cancer had positive Pap brush samples (specificity, ~99{\%}). Next, we showed that intrauterine sampling with a Tao brush increased the detection of malignancy over endocervical sampling with a Pap brush: 93{\%} of 123 (95{\%} CI, 87 to 97{\%}) patients with endometrial cancer and 45{\%} of 51 (95{\%} CI, 31 to 60{\%}) patients with ovarian cancer were positive, whereas none of the samples from 125 women without cancer were positive (specificity, 100{\%}). Finally, in 83 ovarian cancer patients in whom plasma was available, circulating tumor DNA was found in 43{\%} of patients (95{\%} CI, 33 to 55{\%}). When plasma and Pap brush samples were both tested, the sensitivity for ovarian cancer increased to 63{\%} (95{\%} CI, 51 to 73{\%}). These results demonstrate the potential of mutation-based diagnostics to detect gynecologic cancers at a stage when they are more likely to be curable.",
author = "Yuxuan Wang and Lu Li and Christopher Douville and Cohen, {Joshua D} and Ting-Tai Yen and Isaac Kinde and Karin Sundfelt and Kj{\ae}r, {Susanne K} and Hruban, {Ralph H} and Ie-Ming Shih and Tian-Li Wang and Kurman, {Robert J} and Simeon Springer and Janine Ptak and Maria Popoli and Joy Schaefer and Natalie Silliman and Lisa Dobbyn and Tanner, {Edward J} and Ana Angarita and Maria Lycke and Kirsten Jochumsen and Bahman Afsari and Ludmila Danilova and Levine, {Douglas A} and Kris Jardon and Xing Zeng and Jocelyne Arseneau and Lili Fu and Diaz, {Luis A} and Rachel Karchin and Cristian Tomasetti and Kinzler, {Kenneth W} and Bert Vogelstein and Fader, {Amanda N} and Lucy Gilbert and Nickolas Papadopoulos",
note = "Copyright {\circledC} 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.",
year = "2018",
month = "3",
day = "21",
doi = "10.1126/scitranslmed.aap8793",
language = "English",
volume = "10",
pages = "eaap8793",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "433",

}

RIS

TY - JOUR

T1 - Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers

AU - Wang, Yuxuan

AU - Li, Lu

AU - Douville, Christopher

AU - Cohen, Joshua D

AU - Yen, Ting-Tai

AU - Kinde, Isaac

AU - Sundfelt, Karin

AU - Kjær, Susanne K

AU - Hruban, Ralph H

AU - Shih, Ie-Ming

AU - Wang, Tian-Li

AU - Kurman, Robert J

AU - Springer, Simeon

AU - Ptak, Janine

AU - Popoli, Maria

AU - Schaefer, Joy

AU - Silliman, Natalie

AU - Dobbyn, Lisa

AU - Tanner, Edward J

AU - Angarita, Ana

AU - Lycke, Maria

AU - Jochumsen, Kirsten

AU - Afsari, Bahman

AU - Danilova, Ludmila

AU - Levine, Douglas A

AU - Jardon, Kris

AU - Zeng, Xing

AU - Arseneau, Jocelyne

AU - Fu, Lili

AU - Diaz, Luis A

AU - Karchin, Rachel

AU - Tomasetti, Cristian

AU - Kinzler, Kenneth W

AU - Vogelstein, Bert

AU - Fader, Amanda N

AU - Gilbert, Lucy

AU - Papadopoulos, Nickolas

N1 - Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

PY - 2018/3/21

Y1 - 2018/3/21

N2 - We report the detection of endometrial and ovarian cancers based on genetic analyses of DNA recovered from the fluids obtained during a routine Papanicolaou (Pap) test. The new test, called PapSEEK, incorporates assays for mutations in 18 genes as well as an assay for aneuploidy. In Pap brush samples from 382 endometrial cancer patients, 81% [95% confidence interval (CI), 77 to 85%] were positive, including 78% of patients with early-stage disease. The sensitivity in 245 ovarian cancer patients was 33% (95% CI, 27 to 39%), including 34% of patients with early-stage disease. In contrast, only 1.4% of 714 women without cancer had positive Pap brush samples (specificity, ~99%). Next, we showed that intrauterine sampling with a Tao brush increased the detection of malignancy over endocervical sampling with a Pap brush: 93% of 123 (95% CI, 87 to 97%) patients with endometrial cancer and 45% of 51 (95% CI, 31 to 60%) patients with ovarian cancer were positive, whereas none of the samples from 125 women without cancer were positive (specificity, 100%). Finally, in 83 ovarian cancer patients in whom plasma was available, circulating tumor DNA was found in 43% of patients (95% CI, 33 to 55%). When plasma and Pap brush samples were both tested, the sensitivity for ovarian cancer increased to 63% (95% CI, 51 to 73%). These results demonstrate the potential of mutation-based diagnostics to detect gynecologic cancers at a stage when they are more likely to be curable.

AB - We report the detection of endometrial and ovarian cancers based on genetic analyses of DNA recovered from the fluids obtained during a routine Papanicolaou (Pap) test. The new test, called PapSEEK, incorporates assays for mutations in 18 genes as well as an assay for aneuploidy. In Pap brush samples from 382 endometrial cancer patients, 81% [95% confidence interval (CI), 77 to 85%] were positive, including 78% of patients with early-stage disease. The sensitivity in 245 ovarian cancer patients was 33% (95% CI, 27 to 39%), including 34% of patients with early-stage disease. In contrast, only 1.4% of 714 women without cancer had positive Pap brush samples (specificity, ~99%). Next, we showed that intrauterine sampling with a Tao brush increased the detection of malignancy over endocervical sampling with a Pap brush: 93% of 123 (95% CI, 87 to 97%) patients with endometrial cancer and 45% of 51 (95% CI, 31 to 60%) patients with ovarian cancer were positive, whereas none of the samples from 125 women without cancer were positive (specificity, 100%). Finally, in 83 ovarian cancer patients in whom plasma was available, circulating tumor DNA was found in 43% of patients (95% CI, 33 to 55%). When plasma and Pap brush samples were both tested, the sensitivity for ovarian cancer increased to 63% (95% CI, 51 to 73%). These results demonstrate the potential of mutation-based diagnostics to detect gynecologic cancers at a stage when they are more likely to be curable.

U2 - 10.1126/scitranslmed.aap8793

DO - 10.1126/scitranslmed.aap8793

M3 - Journal article

VL - 10

SP - eaap8793

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 433

ER -

ID: 56090600